Correlation of hepatic steatosis with body mass index, serum ferritin level and hepatic fibrosis in Japanese patients with chronic hepatitis C

Hepatology Research

Volumn 37, Issue 4, 2007, Pages 263-269

  Sumida, Yoshio ^a   Kanemasa, Kazuyuki ^a   Fukumoto, Kohei ^a   Yoshida, Naohisa ^a   Sakai, Kyoko ^a  

^a Nara City Hospital   (Japan)

Author keywords

Iron; Lipid peroxidation; Obesity; Oxidative stress

Indexed keywords

ASPARTATE AMINOTRANSFERASE; FERRITIN; HYALURONIC ACID;

ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CORRELATION ANALYSIS; DISEASE SEVERITY; FATTY LIVER; FEMALE; FERRITIN BLOOD LEVEL; HEPATITIS C; HUMAN; INDEPENDENT VARIABLE; IRON STORAGE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MULTIVARIATE ANALYSIS; OBESITY; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; THROMBOCYTE COUNT; UNIVARIATE ANALYSIS;

EID: 33947720963     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00038.x     Document Type: Article

References (44)

1. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology 1991; 15: 567-71.
2. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and auto-immune chronic hepatitis: A comparative analysis. Hepatology 1992; 15: 572-7.
3. Moriya K, Yotsuyanagi H, Shintani Y et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997; 78: 1527-31.
4. Mihm S, Fayyazi A, Hartmann H, Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997; 25: 735-9.
5. Rubbia-Brandt L, Quadri R, Abid K et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33: 106-15.
6. Ikeda K, Chayama K, Saitoh S et al. Hepatitis C virus subtype 3b infection in a hospital in Japan: Epidemiological study. J Gastroenterol 1996; 31: 801-5.
7. Hourigan LF, Macdonald GA, Purdie D et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215-9.
8. Yoshiike N, Matsumura Y, Zaman MM, Yamaguchi M. Descriptive epidemiology of body mass index in Japanese adults in a representative sample from the National Nutrition Survey 1990-1994. Int J Obes Relat Metab Disord 1998; 22: 684-7.
9. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997; 25: 759-68.
10. Sumida Y, Nakashima T, Yoh T et al. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection. J Hepatol 2000; 33: 616-22.
11. Barbaro G, Di Lorenzo G, Ribersani M et al. Serum ferritin and hepatic glutathione concentrations in chronic hepatitis C patients related to the hepatitis C virus genotype. J Hepatol 1999; 30: 774-82.
12. Farinati F, Cardin R, De Maria N et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995; 22: 449-56.
13. Smith BC, Gorve J, Guzail MA et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998; 27: 1695-9.
14. Ichida F, Tsuji T, Omata M et al. New Inuyama classification; new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun 1996; 6: 112-9.
15. Karen Y, Jennifer A, Yokosuka O, Omata M, Resnick RM. Detection of hepatitis C virus RNA by a combined reverse transcription PCR assay: comparison with nested amplication and antibody testing. J Clin Microbiol 1995; 33: 654-7.
16. Tanaka T, Tsukiyama-Kohara K, Yamaguti K et al. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 1994; 19: 1347-53.
17. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998; 29: 198-206.
18. Fujie H, Yotsuyanagi H, Moriya K et al. Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. J Med Virol 1999; 59: 141-5.
19. Lefkowitch JH, Schiff ER, Davis GL et al. Pathological diagnosis of chronic hepatitis C: A muticenter comparative study with chronic hepatitis B. Gastroenterology 1993; 104: 595-603.
20. McGuinness PH, Bishop A, Painter DM, Chan R, MaCaughan GW. Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C. Hepatology 1996; 23: 676-787.
21. Fiore G, Fera G, Napoli N, Vella F, Schiraldi O. Liver steatosis and chronic hepatitis C: A spurious association? Eur J Gastroenterol Hepatol 1996; 8: 125-9.
22. Macdonald GA, Ward PJ, George DK, Powell LW. Iron and fibrosis in non-alcoholic fatty liver disease. Hepatology 2000; 31: 549.
23. Sohda T, Yanai J, Soejima H, Tamura K. Frequencies in the Japanese population of HFE mutations. Biochem Genet 1999; 37: 63-8.
24. Mendler MH, Turlin B, Moirand R et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117: 1155-63.
25. Hui JM, Sud A, Farrell GC et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003; 125: 1695-704.
26. Shintani Y, Fujie H, Miyoshi H et al. Hepatitis C virus infection and diabetes: Direct involvement of insulin resistance. Gastroenterology 2004; 126: 840-8.
27. Assy N, Minuk GY. Serum aspartate but not alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infections in adults. Am J Gastroenterol 2000; 95: 1545-50.
28. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93: 44-8.
29. Park GJH, Lin BP, Ngu MC, Jones DB, Katelaris PH. Aspartate aminotransferase: Alanine aminotransferase ratio in chronic hepatitis C infection. Is it a useful predictor of cirrhosis? J Gastroenterol Hepatol 2000; 15: 386-90.
30. Guéchot J, Poupon R., Giral P, Balkau B, Giboudeau J, Poupon R. Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol 1994; 20: 388-93.
31. Yamada M, Fukuda Y, Koyama Y et al. Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C. J Gastroenterol Hepatol 1996; 11: 646-51.
32. Oberti F, Valsesia E, Pilette C et al. Non-invasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997; 113: 1609-16.
33. Ikeda K, Saitoh S, Kobayashi M et al. Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data. Hepatol Res 2000; 18: 252-66.
34. Poynard T, Bedossa P, Opolon P for the OBSVIRC, METAVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.
35. Poynard T, Bedossa P, METAVIR and CLINIVIR cooperative study groups. Age and platelet count: A simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. J Viral Hepatitis 1997; 4: 199-208.
36. Wong VS, Wight DGD, Palmer CR, Alexander GJM. Fibrosis and other histological features in chronic hepatitis C virus infection: A statistical model. J Clin Pathol 1996; 49: 465-9.
37. Paradis V, Mathurin P, Kollinger M et al. In situ detection of lipid peroxidation in chronic hepatitis C: Correlation with pathological features. J Clin Pathol 1997; 50: 401-6.
38. Friedman SL. The cellular basis of hepatic fibrosis. N Engl J Med 1993; 328: 1828-35.
39. Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997; 113: 1069-73.
40. Nakashima T, Sumida Y, Yoh T et al. Thioredoxin levels in the sera of untreated viral hepatitis patients and those treated with glycyrrhizin or ursodeoxycholic acid. Antioxid Redox Signal 2000; 2: 687-94.
41. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gasroenterol 1994; 89: 986-8.
42. Bonkovsky HL. Therapy of hepatitis C: Other options. Hepatology 1997; 26 (Suppl 1): 143S-151S.
43. Yano M, Hayashi H, Wakusawa S et al. Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C. Am J Gastroenterol 2002; 97: 133-7.
44. Wakusawa S, Ikeda R, Takikawa T, Hayashi H, Yano M, Yoshioka K. Combined phlebotomy and ursodeoxycholic acid treatment in the patients with chronic hepatitis C. Hepatol Res 2000; 18: 54-62.